The evidence that DC-SIGN might be involved in the anti-inflammatory response to IVIg in humans is derived from the observation that DC-SIGN can replace its murine ortholog SIGN-R1 in IL-33-mediated protection from serum-induced arthritis in mice upon sFc treatment (13). This evidence concerns the gene CD209 and arthritic joint disease.